<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B5CC2B3E-A3AF-4A73-86E8-E05D057A6BF0"><gtr:id>B5CC2B3E-A3AF-4A73-86E8-E05D057A6BF0</gtr:id><gtr:name>Nemaura Pharma Limited</gtr:name><gtr:address><gtr:line1>Loughborough Innovation Centre
Charnwood Building
Ashby Road</gtr:line1><gtr:city>Loughborough</gtr:city><gtr:postCode>LE11 3AQ</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B5CC2B3E-A3AF-4A73-86E8-E05D057A6BF0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>B5CC2B3E-A3AF-4A73-86E8-E05D057A6BF0</gtr:id><gtr:name>Nemaura Pharma Limited</gtr:name><gtr:address><gtr:line1>Loughborough Innovation Centre
Charnwood Building
Ashby Road</gtr:line1><gtr:city>Loughborough</gtr:city><gtr:postCode>LE11 3AQ</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>250000.0</gtr:offerGrant><gtr:projectCost>640077.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/AB7E1A3E-BCA4-4E0D-AA72-6750265F4878"><gtr:id>AB7E1A3E-BCA4-4E0D-AA72-6750265F4878</gtr:id><gtr:firstName>Kathryn</gtr:firstName><gtr:surname>Farrar</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=720021"><gtr:id>13241119-B226-4A27-AB7B-2286A63A5F01</gtr:id><gtr:title>Nemaura Continuous Glucose Monitoring (CGM) Patch</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Development of Prototype</gtr:grantCategory><gtr:grantReference>720021</gtr:grantReference><gtr:abstractText>The CGM Patch is a non-invasive continuous glucose monitoring patch that is worn around
the arm or thigh to continuously monitor the blood glucose levels in a patient without the use
of needles, without the need for blood letting and the associated difficulties and potential for
infection, in a very simple user friendly format. The CGM patch consists of a disposable patch
containing a sensor, and a non disposable miniature electronics module with re-chargeable
power source. The system applies a small harmless electrical current to the skin and as a result
leads to the efficient extraction of glucose from the skin into a chamber in the patch where a
glucose sensor periodically detects the level of glucose and stores the data on the internal
memory platform of the patch as well as displaying the glucose reading on an LCD display,
setting off a vibration when the reading is 'out of range'.
The WHO recommendation for diabetics is to monitor their blood glucose levels at least 5-7
times per day, yet most patients fail to do so more than 1-2 times daily due to the difficulties
asociated with blood letting using the finger-prick method. Furthermore health care providers
spend a significant portion of their budget on managing the complications of diabetes. To date
there have not been any continuous non-invasive systems available that are affordable and
reliable. The CGM patch is intended to not only supplement and eventually replace the fingerprick
method, but also to become an entire patient management system. The carers and/or
physician will have the opportunity to help to guide the patient, their diet and lifestyle
according to the trends recorded over weeks and months by the CGM patch, which can be
downloaded to a PC and used for evalaution and patient management. This will lead to a
significant improvement in the quality of life for patients as well as improving their prognosis
by reducing the rate of associated complications, and reducing the burden on the NHS.</gtr:abstractText><gtr:fund><gtr:end>2013-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2011-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>250000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">720021</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>